您当前所在的位置:首页 > 产品中心 > 产品信息
Baclofen_分子结构_CAS_1134-47-0)
点击图片或这里关闭

Baclofen

产品号 DB00181 公司名称 DrugBank
CAS号 1134-47-0 公司网站 http://www.ualberta.ca/
分子式 C10H12ClNO2 电 话 (780) 492-3111
分子量 213.66078 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 66

产品价格信息

请登录

产品别名

标题
Baclofen
IUPAC标准名
4-amino-3-(4-chlorophenyl)butanoic acid
IUPAC传统名
baclofen
商标名
Lioresal Intrathecal
Kemstro
Lioresal
Baclon
Nu-Baclofen
Pms-Baclofen

产品登记号

PubChem SID 46508181
CAS号 1134-47-0
PubChem CID 2284

产品性质

疏水性(logP) 1.3
溶解度 2090 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Baclofen is a gamma-amino-butyric acid (GABA) derivative used as a skeletal muscle relaxant. Baclofen stimulates GABA-B receptors leading to decreased frequency and amplitude of muscle spasms. It is especially useful in treating muscle spasticity associated with spinal cord injury. It appears to act primarily at the spinal cord level by inhibiting spinal polysynaptic afferent pathways and, to a lesser extent, monosynaptic afferent pathways.
Indication For the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.
Pharmacology Baclofen is a muscle relaxant and antispastic. Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Although Baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects. In studies with animals, Baclofen has been shown to have general CNS depressant properties as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression. Baclofen is rapidly and extensively absorbed and eliminated. Absorption may be dose-dependent, being reduced with increasing doses. Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.
Toxicity LD50=45 mg/kg (male mice, IV); LD50=78 mg/kg (male rat, IV)
Affected Organisms
Humans and other mammals
Biotransformation ~ 15% of the dose is metabolized in the liver, primarily by deamination. 70-80% of the dose is excreted unchanged or as metabolites in urine and the remainder is excreted in feces.
Absorption Rapidly and almost completely absorbed from the GI tract.
Half Life 2.5-4 hours
Protein Binding 30%
Elimination In a study using radiolabeled baclofen, approximately 85% of the dose was excreted unchanged in the urine and feces.
Baclofen is excreted primarily by the kidney as unchanged drug; 70 - 80% of a dose appears in the urine as unchanged drug. The remainder is excreted as unchanged drug in the feces or as metabolites in the urine and feces.
Distribution * 59 L
Clearance * 180 mL/min
References
Dzitoyeva S, Dimitrijevic N, Manev H: Gamma-aminobutyric acid B receptor 1 mediates behavior-impairing actions of alcohol in Drosophila: adult RNA interference and pharmacological evidence. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5485-90. Epub 2003 Apr 11. [Pubmed]
Mezler M, Muller T, Raming K: Cloning and functional expression of GABA(B) receptors from Drosophila. Eur J Neurosci. 2001 Feb;13(3):477-86. [Pubmed]
See S, Ginzburg R: Skeletal muscle relaxants. Pharmacotherapy. 2008 Feb;28(2):207-13. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

参考文献

  • Dzitoyeva S, Dimitrijevic N, Manev H: Gamma-aminobutyric acid B receptor 1 mediates behavior-impairing actions of alcohol in Drosophila: adult RNA interference and pharmacological evidence. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5485-90. Epub 2003 Apr 11. Pubmed
  • Mezler M, Muller T, Raming K: Cloning and functional expression of GABA(B) receptors from Drosophila. Eur J Neurosci. 2001 Feb;13(3):477-86. Pubmed
  • See S, Ginzburg R: Skeletal muscle relaxants. Pharmacotherapy. 2008 Feb;28(2):207-13. Pubmed